Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 908 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Age - Related Macular Degeneration (AMD) Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)

NCT03539549
View directory record Official record
Conditions
Macular Degeneration
Interventions
Abicipar pegol
Drug
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 15, 2026, 5:41 PM EDT
Recruiting Phase 1 Interventional

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

NCT03178149
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin
Drug
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 15, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional Results available

Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)

NCT00668785
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Jumper, J. Michael, M.D.
Individual
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 15, 2026, 5:41 PM EDT
Completed No phase listed Observational

AMD Ryan Initiative Study (ARIS)

NCT03092492
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 120 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 15, 2026, 5:41 PM EDT
Active, not recruiting No phase listed Observational

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

NCT06779773
View directory record Official record
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
Avacincaptad pegol (ACP)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
Not listed
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 15, 2026, 5:41 PM EDT
Terminated No phase listed Observational

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

NCT03894020
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Retinal Degeneration, Geographic Atrophy, Macular Atrophy
Interventions
Not listed
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 15, 2026, 5:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

NCT02338973
View directory record Official record
Conditions
Inherited Ophthalmic Diseases, Inherited Retinal Degeneration
Interventions
Interferon gamma-1b
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 15, 2026, 5:41 PM EDT
Terminated Phase 1Phase 2 Interventional

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

NCT00358423
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Pegaptanib Sodium, Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2008 · Synced Oct 15, 2026, 5:41 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion

NCT01827722
View directory record Official record
Conditions
Macular Edema, Central Retinal Vein Occlusion
Interventions
Ozurdex, Ranibizumab, Combination Ozurdex with Ranibizumab PRN
Drug
Lead sponsor
Valley Retina Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
5
States / cities
Beverly Hills, California • Lakeland, Florida • Winter Haven, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 15, 2026, 5:41 PM EDT
Active, not recruiting No phase listed Observational

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

NCT04645212
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
9
States / cities
Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 15, 2026, 5:41 PM EDT
Completed Phase 1 Interventional

Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema

NCT00069056
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Laser Treatment
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 5:41 PM EDT
Recruiting Phase 1 Interventional

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

NCT06319872
View directory record Official record
Conditions
Alcohol Use Disorder, Retinal Dystrophies, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
Interventions
Oral disulfiram
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 15, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

NCT02022501
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
DE-120
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Bakersfield, California • Beverly Hills, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 15, 2026, 5:41 PM EDT
Terminated Phase 3 Interventional Results available

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

NCT04757636
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
2.0 mg OPT-302, 2.0 aflibercept, Sham
Biological · Procedure
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
60
States / cities
Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 15, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy

NCT00470977
View directory record Official record
Conditions
Coats' Disease, Idiopathic Retinal Telangiectasia, Retinal Angiomatous Proliferation, Polypoidal Choroidal Vasculopathy, Pseudoxanthoma Elasticum, Pathological Myopia, Multi-focal Choroiditis, Rubeosis Iridis, Von Hippel Lindau Disease, BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Interventions
ranibizumab injection (0.5 mg)
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 15, 2026, 5:41 PM EDT
Completed Early Phase 1 Interventional Results available

Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation

NCT03478865
View directory record Official record
Conditions
AMD
Interventions
Vitamin A palmitate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 15, 2026, 5:41 PM EDT
Completed Not applicable Interventional

Long Term Safety of Cooling Anesthesia for Intravitreal Injection

NCT03956797
View directory record Official record
Conditions
Anesthesia, Local, Intravitreal Injection, Macular Edema, Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Recens Cooling Anesthesia Device
Device
Lead sponsor
Recens Medical, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Reno, Nevada • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 15, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

NCT01449682
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Ozurdex
Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 15, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

NCT01002950
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy
Interventions
ACU-4429, Matching placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Phoenix, Arizona • Beverly Hills, California • Daytona Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 15, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

NCT03927690
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
LKA651, Lucentis
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 15, 2026, 5:41 PM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

NCT06132035
View directory record Official record
Conditions
Age-related Wet Macular Degeneration
Interventions
CG-P5 peptide, Placebo, Aflibercept Injection [Eylea]
Drug
Lead sponsor
Caregen Co. Ltd.
Industry
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 15, 2026, 5:41 PM EDT
Recruiting No phase listed Observational

Study of BEST1 Vitelliform Macular Dystrophy

NCT05809635
View directory record Official record
Conditions
Best Vitelliform Macular Dystrophy, Retinitis Pigmentosa
Interventions
Natural History Study
Other
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 15, 2026, 5:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial

NCT02374060
View directory record Official record
Conditions
Macular Edema, Uveitis
Interventions
Periocular triamcinolone 40 mg, Intravitreal triamcinolone 4 mg, Dexamethasone intravitreal implant
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 15, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of X-82 in Patients With Wet AMD

NCT01674569
View directory record Official record
Conditions
Exudative Macular Degeneration
Interventions
X-82 oral, ranibizumab (Lucentis)
Drug
Lead sponsor
Tyrogenex
Industry
Eligibility
50 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Beverly Hills, California • New London, Connecticut • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 15, 2026, 5:41 PM EDT